- Home
- KRMD vs VTYX Comparison
KRMD vs VTYX Comparison
Compare KRMD & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRMD
- VTYX
- Stock Information
- Founded
- KRMD 1980
- VTYX 2018
- Country
- KRMD United States
- VTYX United States
- Employees
- KRMD N/A
- VTYX N/A
- Industry
- KRMD Medical/Dental Instruments
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- KRMD Health Care
- VTYX Health Care
- Exchange
- KRMD Nasdaq
- VTYX Nasdaq
- Market Cap
- KRMD 134.3M
- VTYX 154.9M
- IPO Year
- KRMD N/A
- VTYX 2021
- Fundamental
- Price
- KRMD $3.62
- VTYX $2.08
- Analyst Decision
- KRMD Strong Buy
- VTYX Buy
- Analyst Count
- KRMD 4
- VTYX 4
- Target Price
- KRMD $4.63
- VTYX $11.33
- AVG Volume (30 Days)
- KRMD 456.1K
- VTYX 2.2M
- Earning Date
- KRMD 08-06-2025
- VTYX 08-07-2025
- Dividend Yield
- KRMD N/A
- VTYX N/A
- EPS Growth
- KRMD N/A
- VTYX N/A
- EPS
- KRMD N/A
- VTYX N/A
- Revenue
- KRMD $35,083,740.00
- VTYX N/A
- Revenue This Year
- KRMD $18.16
- VTYX N/A
- Revenue Next Year
- KRMD $14.60
- VTYX N/A
- P/E Ratio
- KRMD N/A
- VTYX N/A
- Revenue Growth
- KRMD 19.65
- VTYX N/A
- 52 Week Low
- KRMD $1.86
- VTYX $0.78
- 52 Week High
- KRMD $5.05
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- KRMD 68.65
- VTYX 47.92
- Support Level
- KRMD $3.45
- VTYX $1.95
- Resistance Level
- KRMD $3.77
- VTYX $2.51
- Average True Range (ATR)
- KRMD 0.22
- VTYX 0.19
- MACD
- KRMD 0.02
- VTYX -0.08
- Stochastic Oscillator
- KRMD 85.48
- VTYX 19.12
About KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.